American Gene Technologies (AGT), a gene technology company with a broad, robust lentiviral delivery platform, announced today that the CEO, Jeff Galvin is presenting at the upcoming BIO CEO & Investor conference. The Conference is being held on February 13 -14, at the Waldorf Astoria New York, New York. The presentation is schedule for Monday February 13, 2017 at 2:15 PM. Interested Investors and collaborators are encouraged to schedule one-on-one meetings.
About American Gene Technologies
American Gene Technologies International Inc. was founded in 2008 and has developed its technology platform and related intellectual property at its Rockville, Maryland laboratories. AGT recently advanced one of its target therapeutics to the final preclinical phase with a successful pre-IND meeting with the FDA. An IND application is being finalized to initiate a Phase 1 human trial for an HIV cure that will evaluate safety of an autologous cell product. AGT anticipates initiating human trials this year for HIV. In parallel, AGT is actively developing INDs for phenylketonuria (“PKU”) and hepatocellular carcinoma (“HCC”). AGT has developed extensive IP surrounding lentiviral platform innovations that accelerate the development of a wide variety of drug candidates, provides significant opportunities for out-licensing, and offers exciting clinical opportunities in large and orphan indications, complex diseases, and monogenic disorders.
BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.